Defining the clinical course of multiple sclerosisFred Lublin, Chris H. Polman, Stephen C. Reingold et al.|Neurology|2014Cited by 3.1k
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trialLudwig Kappos, Paul D. Crowe, Giancarlo Comi et al.|Nature Medicine|2000Cited by 515
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosisAlena Novotná, Jan Mareš, S. Ratcliffe et al.|European Journal of Neurology|2011Cited by 465
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosisP. D. Molyneux, D. H. Miller, Ludwig Kappos et al.|Brain|2000Cited by 241
Interferon beta-1b in secondary progressive MSLudwig Kappos, Henry F. McFarland, Brian G. Weinshenker et al.|Neurology|2004Cited by 223